Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Indian J Cancer
;
2016 Jan-Mar; 53(1): 118-122
Article
Dans Anglais
| IMSEAR
| ID: sea-176793
ABSTRACT
BACKGROUND:
The 5‑year survival rate for metastatic renal cell carcinoma (RCC) is estimated to be <10%. RCC is highly resistant to chemotherapy. Targeted agents are now first choice of therapy for metastatic RCC such as sunitinib and sorafenib.METHODS:
This study is a retrospective analysis of 15 patients having metastatic RCC treated with sunitinib. Apart from three patients, all had clear cell histology. Thirteen patients received dosage of 50 mg/d (4 weeks on/2 weeks off cycles). In 14 patients sunitinib was used as 1st line. The primary end point was objective response rate. Secondary end points were progression free survival (PFS) and safety.RESULTS:
Until date of reporting, 3 out of 15 patients are currently on sunitinib. The most common Memorial Sloan = Kettering Cancer Centre poor prognostic factor was an interval of <1 year between diagnosis and starting of treatment (80%). The objective response rate was 13.66% (complete response [CR] + partial response [PR] = 0 + 2). Clinical benefit rate (CR + PR + stable disease) was 60% (n = 9). Median PFS in this study was 7.5 months, with a range of 2‑22 month. Median overall survival (OS) of patients in this study was 12 months with a range of 3‑24 month. An impact of the dose or/and number of cycles on response was seen in this study, with patients having average cycles >3 showing better response rates, PFS and OS. Major toxicities seen were fatigue ( n = 7), diarrhea (n = 3) and skin rash (n = 4) with majority patients experienced Grade 1‑2 toxicities. While Grade 3‑4 toxicities include fatigue (n = 1), mucositis (n = 1) and nausea (n = 1).CONCLUSIONS:
These results confirm efficacy and safety profile of sunitinib in metastatic RCC, particularly as a first line. Sunitinib produced a 60% disease control rate for metastatic RCC in Indian patients, with acceptable rates of toxicity at a dose of 50 mg daily. Response rates were well matched to other studies confirming the efficacy of sunitinib.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Type d'étude:
Étude pronostique
langue:
Anglais
Texte intégral:
Indian J Cancer
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS